Venmax Drugs & Pharmaceuticals Ltd (VENMAX) — shareholding pattern, promoter holding, financials and share price
About Venmax Drugs & Pharmaceuticals Ltd (VENMAX)
Venmax Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VENMAX and on the BSE under scrip code 531015. Its ISIN is INE154G01022.
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services [1]
Venmax Drugs & Pharmaceuticals Limited (VDPL) is primarily engaged in pharmaceutical product manufacturing, focusing on drug intermediaries and APIs.
Recently, the company has ventured into establishing a chain of medical stores under the 'Ananya Pharma' brand, supported by its formulations plant, Suzichem Labs.
Listed peers in Pharmaceuticals: Ishita Drugs & Industries Ltd, Cian Healthcare Ltd, Centuple Global Ltd, Rekvina Labs Ltd, Mono Pharmacare Ltd, Desh Rakshak Aushdhalaya Ltd.
Valuation & Returns
10 Jul 2026At ₹19.46 a share on 10 Jul 2026, Venmax Drugs & Pharmaceuticals Ltd (VENMAX) was valued at a price-to-earnings ratio of 112.7x against an industry P/E of 36.41x and a price-to-book of 5.11x on a book value of ₹3.81 per share as of Mar 2025. Solomo computes return on equity of 4.53% and return on capital employed of 5.16% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 112.7x
- Industry P/E
- 36.41x
- P/B
- 5.11x
- EPS (TTM)
- ₹0.17
- Book value / share
- ₹3.81
- ROE
- 4.53%
- ROCE
- 5.16%
- ROA
- 3.87%
- Debt / equity
- 0.01x
- Dividend yield
- 0%
- EBITDA margin
- 2.99%
- 52-week range
- ₹16 – ₹36.96
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Venmax Drugs & Pharmaceuticals Ltd (VENMAX) reported revenue of ₹8.02 crore, net profit of ₹0.25 crore and earnings per share of ₹0.22. That compares with revenue of ₹0.81 crore and net profit of ₹-0.01 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3.94 crore and net profit ₹0.11 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 0 | 0 | 0.81 | 8.02 |
| Net profit (₹ cr) | 1.85 | 0.23 | 0.06 | -0.01 | 0.25 |
| EPS (₹) | 3.53 | 0.44 | 0.11 | -0.02 | 0.22 |
| Measure | 10Y | 5Y | 1Y |
|---|---|---|---|
| Sales growth | -9.23% | 11.32% | - |
| Profit growth | - | - | -116.67% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 10.46% of Venmax Drugs & Pharmaceuticals Ltd (VENMAX) (down 3.34 pp QoQ). Market capitalisation was ₹23 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: PUSHPA BHAJU 12.95%, JUGAL KISHORE BHAGAT 11.22%, MANISH GROVER 4.75%, PERCY HOMI ITALIA 4.02%, WCA SERVICES PRIVATE LIMITED 3.48%, MEGA FLEX PLASTICS LIMITED 2.59%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 10.46% | - | - | - | 89.54% |
| Mar 2026 | 13.8% | - | - | - | 86.2% |
| Dec 2025 | 15.14% | - | - | - | 84.86% |
| Sep 2025 | 23.13% | - | - | - | 76.87% |
| Jun 2025 | 23.13% | - | - | - | 76.87% |
| Mar 2025 | 23.13% | - | - | 0.15% | 76.87% |
| Dec 2024 | 23.13% | - | - | 0.15% | 76.87% |
| Sep 2024 | 23.13% | - | - | 0.15% | 76.87% |